Navigation Links
Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Date:3/6/2013

CARLSBAD, Calif., March 6, 2013 /PRNewswire/ -- Isis Pharmaceuticals, Inc. (NASDAQ: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Barclays Global Healthcare Conference on Wednesday, March 13, 2013 at 2:00 p.m. ET in Miami, FL.

A live audio webcast of the presentation will be available on the "Investors & Media" section of the Company's Web site, www.isispharm.com.  A replay will be available on the Isis Web site within 48 hours and will be archived for a limited time.

ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover and develop novel drugs for its product pipeline and for its partners.  Isis' broad pipeline consists of 28 drugs to treat a wide variety of diseases with an emphasis on cardiovascular, metabolic, severe and rare diseases, and cancer.  Isis' partner, Genzyme, is commercializing Isis' lead product, KYNAMRO™, in the United States for the treatment of patients with HoFH.  Genzyme is also pursuing marketing approval of KYNAMRO in other markets, including Europe.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements regarding Isis' business and the therapeutic potential of Isis' technologies and products in development.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, Inc.  Regulus Therapeutics™ is a trademark of Regulus Therapeutics Inc.  KYNAMRO™ is a trademark of Genzyme Corporation.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Jazz Pharmaceuticals Announces Pricing Of Public Offering Of Ordinary Shares By Selling Shareholders
2. Tarix Pharmaceuticals Peptide Technology Stimulates Revascularization Following Ischemia
3. Aquavit Pharmaceuticals Inc. Appoints David Shafer, MD., FACS., New Chief Medical Technology Officer
4. TauRx Pharmaceuticals Receives $10.5m Follow-On Investment from Dundee Corporation
5. Jazz Pharmaceuticals Announces Public Offering Of Ordinary Shares By Selling Shareholders
6. Imprimis Pharmaceuticals Out Licenses Its Proprietary IP to resolutionMD for Cosmeceutical Products
7. Auxilium Pharmaceuticals, Inc. to Present at the Cowen and Company 33rd Annual Healthcare Conference
8. Arena Pharmaceuticals Provides Corporate Update and Reviews Fourth Quarter and Full Year 2012 Financial Results
9. AVANIR Pharmaceuticals To paticipate in two conferences in March
10. Cadence Pharmaceuticals To Host Conference Call And Webcast To Discuss Fourth Quarter And Full Year 2012 Financial Results On March 7, 2013
11. Adamis Pharmaceuticals Prevails in License Dispute Litigation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... February 12, 2016 ... titled Chronic Inflammation Global Clinical Trials Review, H2, ... the global clinical trials landscape along with top ... Region, Country (G7 & E7), Trial Status, Trial ... reviews top companies involved and enlists all trials ...
(Date:2/11/2016)... 2016 Laboratory glassware and plasticware ... These may range from microscope slides to large storage ... from borosilicate glass because of its low weight and ... hand, started gaining popularity over the past decade when ... glass with plastic in several applications due to its ...
(Date:2/11/2016)... 11, 2016 Potrero Medical, Inc., the developer of ... the appointment of George M. Rapier, III , MD, ... TX , WellMed is one of the nation,s largest ... HMO members in Texas and ... of his own internal medicine practice, he has been instrumental ...
Breaking Medicine Technology:
(Date:2/12/2016)... ... February 12, 2016 , ... Every winter, someone is killed, injured or ... West Penn Burn Center, part of the Allegheny Health Network, has partnered with ... the “Space Heaters Need Space” campaign. , “Space Heaters Need Space” aims ...
(Date:2/12/2016)... ... , ... The Jones Agency, a family owned insurance company with offices serving ... charity drive with the Tarrant Area Food Bank in the hopes of alleviating hunger ... need, the Tarrant County Food Bank offers hope and security to the one in ...
(Date:2/12/2016)... ... February 12, 2016 , ... Young ... area, celebrates the beginning of the latest charity campaign in their community enrichment ... art. Donations to this worthy cause are currently being accepted at: http://artexpressioninc.org/ ...
(Date:2/12/2016)... ... ... For Coast Dental dentist Everet Lake, DDS, the smiles began at dawn. ... before 7 a.m. to volunteer at Friday’s Dentistry from the Heart event in New ... help hundreds of uninsured and underinsured people receive much-needed dental care. , This ...
(Date:2/12/2016)... ... February 12, 2016 , ... ... foods choices that promote eye health. These articles generally list between five and ... health advocate Sharon Kleyne endorses every one of these lists and believes that ...
Breaking Medicine News(10 mins):